Michigan’s Henry Ford Health System has purchased Gamma Medica’s LumaGem molecular breast imaging system. Slated for installation by the end of the year at West Bloomfield Township-based Henry Ford West Bloomfield Hospital, the platform will be used as a secondary screening and diagnostic tool after x-ray mammography, in particular for women with dense breast tissue. The benefit to the health system is the ability to take advantage of this imaging modality to improve cancer detection rates in women, especially those who are at increased risk.
“Henry Ford Health System’s commitment to install our LumaGem [molecular breast imaging] system validates progress in giving all women, regardless of their breast density, access to accurate breast cancer screenings,” says Philip Croxford, president and CEO of Gamma Medica.
He adds that his company is pleased to partner with “such an influential and respected healthcare system such as Henry Ford” and looks forward to helping provide women with access to early detection methods.
“Our goal is to give patients the latest, safest, and best quality care by continuing to evolve the ways we help our patients and providers be certain in their test results,” says Patricia Miller, MD, director of the Breast Imaging Center at Henry Ford West Bloomfield Hospital.
Miller points to research and real-world evidence that illustrates the unique value of molecular breast imaging to a patient population that is sorely in need of it. “Given the proven significant increase in cancer detection rates through the use of the LumaGem [molecular breast imaging] system, we are confident this installation will help us diagnose breast cancer early, specifically for our patients with dense breast tissue.”
For more information about this system, visit Gamma Medica.
